Citadel Advisors’s Odyssey Therapeutics ODTX Stock Holding History

Citadel Advisors’s Portfolio ODTX Stock Details ODTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.16M	Buy	+222,450	New	+$3.9M	﹤0.01%	5059

Other funds holding ODTX

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

LMC

Lightspeed Management Company Menlo Park, California $2.4B AUM 7.07% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCMV

Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Citadel Advisors's ODTX Position: Q2 2026 in Review

Citadel Advisors opened a new position in Odyssey Therapeutics (ODTX) in Q2 2026: 222,450 shares worth $4.16M. The stake represents ﹤0.01% of the portfolio and ranks #5059 among its holdings.

50 funds tracked by Wall St. Rank hold ODTX as of Q2 2026.

Citadel Advisors held 222,450 shares of Odyssey Therapeutics worth $4.16M as of Q2 2026.
Odyssey Therapeutics was a new Citadel Advisors position in Q2 2026.
Odyssey Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5059 holding.
50 funds tracked by Wall St. Rank held Odyssey Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.